Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001438533 · TVTX · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001438533 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Travere Therapeutics, Inc. (NASDAQ: TVTX) has submitted 1,002+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2012. As a Healthcare sector company with CIK 0001438533, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Travere Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Travere Therapeutics, Inc. 10-K was filed on 2026-02-19 for fiscal year ending 2026. Historical TVTX 10-K annual reports are available from 2015 through 2026.
Investors researching Travere Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
TVTX SEC Filings · 8 questionsTravere Therapeutics, Inc. (TVTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,002+ filings and access original documents at no cost. Travere Therapeutics, Inc.'s CIK is 0001438533.